Mederi Therapeutics Inc. is a Greenwich, Connecticut–based medical device manufacturer focused on radiofrequency (RF) therapies for digestive disorders. The company markets the Stretta therapy for gastroesophageal reflux disease (GERD) and the Secca therapy for bowel incontinence. Both therapies are minimally invasive treatments that use RF energy to remodel the muscles controlling the entry and exit of the digestive tract. Led by CEO Will Rutan, Mederi aims to broaden clinical adoption of its device-based treatments. The company recently completed an $18.5M financing (Series B preferred stock plus venture debt) and plans to use the proceeds to expand adoption of its therapies.

Total raised

$19M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2014